Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.98 USD
-0.19 (-15.95%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.98 +0.01 (0.51%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Aptose Biosciences, Inc. [APTO]
Reports for Purchase
Showing records 61 - 80 ( 144 total )
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -New Leukemia Approvals - Their Implications
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Results; Driving Fast Toward Clinical Initiations
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Oh, the Woes of Retail Volatility and Misperceptions; Thesis Remains Strong; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Soon At Trial Centers Near You; Reiterate Buy - $7 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q18 Results; Soon Stepping up to the Plate: ''806 and ''253; We Like the Odds
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Independence Day Weekend Now Includes Freedom From Clinical Hold for ''253; Target Increased to $8.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
The Comeback Kid; Reiterate Buy - Raising PT to $7
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - ORD-ARN-JFK: Crossing Our Onco Radar
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CG-806 Smashes Ibrutinib in Head to Head Preclinical Studies Including Primary Patient Samples
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
The Whole World Could Be CG-806''s Oyster Now; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Results; On the Verge of Critical Inflection Points With Both Lead Drugs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
APTO-253 Profile Solidifies as Clinical Program Expected to Resume Shortly; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Broad Set of Primary Patient Samples Connect Important Dots Toward Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
BTK Value of CG''806 in Better Focus; Reiterate Buy - Raising PT to $6
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J